/**
 * Hardcoded SEO blog post: /blog/turkey-pharmaceutical-market-2026-titck-top-companies
 * Pharma-specific companion to /turkey-healthcare-market-report and
 * /turkey-medical-devices-market-report, which cover the broader system and devices.
 * This piece leads with TITCK regulatory process and a company directory.
 */
import type { BlogPost } from '@/types/blog';

export const TURKEY_PHARMA_2026_SLUG = 'turkey-pharmaceutical-market-2026-titck-top-companies';

export const TURKEY_PHARMA_2026_COVER_IMAGE =
  'https://images.unsplash.com/photo-1584017911766-d451b3d0e843?w=1600&h=900&fit=crop&q=85';

export const TURKEY_PHARMA_2026_META_TITLE =
  'Turkey Pharmaceutical Market 2026: Size, TITCK & Top Companies | BioNixus';

export const TURKEY_PHARMA_2026_META_DESCRIPTION =
  "Turkey's pharmaceutical market in 2026 — size and growth, TITCK drug registration steps, reference pricing, and the leading local and multinational companies.";

export const TURKEY_PHARMA_2026_DISPLAY_TITLE =
  'Turkey Pharmaceutical Market 2026: Size, TITCK & Top Companies';

export const TURKEY_PHARMA_2026_PUBLISHED_ISO = '2026-07-22T09:00:00.000Z';
export const TURKEY_PHARMA_2026_UPDATED_ISO = '2026-07-22T09:00:00.000Z';

export const TURKEY_PHARMA_2026_TABLE_OF_CONTENTS: { heading: string; anchor: string }[] = [
  { heading: 'Market size and growth', anchor: 'market-size' },
  { heading: 'How TITCK drug registration works', anchor: 'titck-registration' },
  { heading: 'Top pharmaceutical companies in Turkey', anchor: 'top-companies' },
  { heading: 'What this means for market entry', anchor: 'market-entry' },
];

export const TURKEY_PHARMA_2026_EXECUTIVE_SUMMARY_HTML = `<p><strong>What buyers need to know about Turkey pharma in 2026</strong></p>
<ul>
<li><strong>Market size</strong> — Turkey's pharmaceutical market was valued at approximately USD 10.5 billion in 2025, projected to reach roughly USD 15.6 billion by 2035 at a 4.0% CAGR (IMARC Group); other estimates put the current market closer to USD 12 billion.</li>
<li><strong>Regulator</strong> — TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu) approved 225 new drugs in 2023, including 8 biosimilars, via an ICH-aligned CTD dossier submitted through its electronic Online Application System (OAS).</li>
<li><strong>Pricing</strong> — TITCK references drug prices in five countries — Portugal, Spain, France, Italy, and Greece — as part of its pricing review.</li>
<li><strong>Companies</strong> — 300+ local manufacturers and 50+ multinational subsidiaries operate in Turkey, led by Abdi İbrahim, Eczacıbaşı, Bilim İlaç, Sanovel, and Deva Holding domestically, alongside Novartis Türkiye, Sanofi Türkiye, Pfizer Türkiye, Bayer Türkiye, and Roche Group.</li>
</ul>`;

export const TURKEY_PHARMA_2026_SCHEMA_FAQ: { question: string; answer: string }[] = [
  {
    question: "How big is Turkey's pharmaceutical market in 2026?",
    answer:
      "Turkey's pharmaceutical market was valued at approximately USD 10.5 billion in 2025, projected to reach roughly USD 15.6 billion by 2035 at a 4.0% CAGR, according to IMARC Group. Other third-party estimates put the current market closer to USD 12 billion — a reasonably consistent range compared to some other emerging markets, without a major methodology split.",
  },
  {
    question: 'How does TITCK drug registration work in Turkey?',
    answer:
      "TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — the Turkish Medicines and Medical Devices Agency) requires dossiers in the Common Technical Document (CTD) format, aligned with International Council for Harmonisation (ICH) standards, covering new drugs, generics, hybrids, and biosimilars. Submissions are made electronically through TITCK's Online Application System (OAS), which requires an electronic submission agreement and processed fees before dossier filing. Dossier validation — a format-and-content review — is the formal start of the registration process. Required documentation includes scientific data, administrative documents on the applicant's legal status, and a GMP certificate. TITCK approved 225 new drugs in 2023, including 8 biosimilars.",
  },
  {
    question: 'How is pharmaceutical pricing regulated in Turkey?',
    answer:
      "TITCK's pricing review references drug prices from five countries — Portugal, Spain, France, Italy, and Greece — as part of its evaluation process. This reference-pricing basket is a key input companies must plan around when sequencing a Turkey launch alongside these five European markets.",
  },
  {
    question: 'Who are the leading pharmaceutical companies in Turkey?',
    answer:
      "Turkey's pharmaceutical sector includes 300+ local manufacturers and 50+ multinational subsidiaries. Leading local companies include Abdi İbrahim (which operates AbdiBio, described as one of Turkey's largest biotech manufacturing investments, targeting monoclonal antibody production), Eczacıbaşı, Bilim İlaç, Sanovel, and Deva Holding. Major multinational subsidiaries operating in-market include Novartis Türkiye, Sanofi Türkiye, Pfizer Türkiye, Bayer Türkiye, and Roche Group. This reflects the leading companies active in Turkey rather than a single definitive ranked list, since no one authoritative ranking source covers the full market.",
  },
  {
    question: 'How does BioNixus support pharmaceutical companies entering the Turkish market?',
    answer:
      "BioNixus runs Turkey-specific pharmaceutical and healthcare market research, including SGK-aligned market access evidence design — Turkey's General Health Insurance system (SGK) covers approximately 98% of the population, making SGK reimbursement strategy central to any Turkey launch plan. BioNixus positions Turkey research alongside its wider GCC and MENA coverage, helping companies sequence Turkey launches against reference-pricing baskets and regional access strategy.",
  },
];

export const TURKEY_PHARMA_2026_TAGS = [
  'Turkey pharmaceutical market',
  'TITCK registration',
  'Turkey market access',
  'SGK reimbursement',
  'Turkey pharma companies',
] as const;

export const TURKEY_PHARMA_2026_SCHEMA_ITEM_LIST = {
  name: 'Turkey pharmaceutical market and regulatory themes',
  items: [
    {
      name: 'Market size and growth',
      description:
        'USD 10.5 billion in 2025, projected to reach roughly USD 15.6 billion by 2035 at a 4.0% CAGR (IMARC Group).',
    },
    {
      name: 'TITCK CTD dossier and OAS submission',
      description:
        'ICH-aligned CTD dossiers submitted electronically via the Online Application System, with dossier validation as the formal review start.',
    },
    {
      name: 'Five-country reference pricing',
      description: 'TITCK references prices in Portugal, Spain, France, Italy, and Greece during pricing review.',
    },
    {
      name: 'Local and multinational manufacturers',
      description: '300+ local manufacturers and 50+ multinational subsidiaries operating in Turkey.',
    },
  ],
};

export const TURKEY_PHARMA_2026_BODY_HTML = `<p>Turkey's pharmaceutical market was valued at approximately USD 10.5 billion in 2025, projected to reach roughly USD 15.6 billion by 2035 at a 4.0% CAGR (IMARC Group); other estimates put the current market closer to USD 12 billion. The market is regulated by TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu), which approved 225 new drugs in 2023, including 8 biosimilars. Turkey's pharmaceutical sector includes 300+ local manufacturers and 50+ multinational subsidiaries; leading local players include Abdi İbrahim, Eczacıbaşı, Bilim İlaç, Sanovel, and Deva Holding, alongside multinational subsidiaries such as Novartis Türkiye, Sanofi Türkiye, Pfizer Türkiye, Bayer Türkiye, and Roche Group.</p>

<p>For BioNixus's broader Turkey healthcare and devices coverage, see the <a href="/turkey-healthcare-market-report">Turkey Healthcare Market Report</a> and the <a href="/turkey-medical-devices-market-report">Turkey Medical Devices Market Report</a>. This piece focuses specifically on the pharmaceutical market, TITCK registration, and the company landscape.</p>

<h2 id="market-size">Market size and growth</h2>

<p>IMARC Group values Turkey's pharmaceutical market at approximately USD 10.5 billion in 2025, projecting growth to roughly USD 15.6 billion by 2035 at a 4.0% CAGR. Other third-party estimates put the current market closer to USD 12 billion — a reasonably consistent range across sources, without the wide methodology-driven spread seen in some other emerging pharma markets. Turkey's position as a bridge market between the GCC report cluster and EU5 pricing dynamics — discussed further below — is a structural factor behind this steady growth trajectory.</p>

<h2 id="titck-registration">How TITCK drug registration works</h2>

<p>TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — the Turkish Medicines and Medical Devices Agency) governs pharmaceutical registration in Turkey. Key elements of the process:</p>
<ul>
<li><strong>CTD dossier format</strong> — Turkey mandates the Common Technical Document (CTD) format, aligned with International Council for Harmonisation (ICH) standards, with module requirements varying by application type (new drug vs. abbreviated formats such as generics, hybrids, or biosimilars).</li>
<li><strong>Electronic submission via OAS</strong> — All submissions go through TITCK's Online Application System (OAS), requiring a signed electronic submission agreement and processed fees prior to dossier filing.</li>
<li><strong>Dossier validation</strong> — The formal start of the registration process is dossier validation: a review of the submitted dossier's format and content.</li>
<li><strong>Required documentation</strong> — Scientific data, administrative documents establishing the applicant's legal status, and a GMP certificate must be included in the appropriate CTD modules.</li>
<li><strong>Reference pricing</strong> — TITCK's pricing review references drug prices in five countries: Portugal, Spain, France, Italy, and Greece.</li>
</ul>
<p>TITCK approved 225 new drugs in 2023, including 8 biosimilars — a useful recent-activity benchmark for approval volumes and biosimilar momentum in the market.</p>

<h2 id="top-companies">Top pharmaceutical companies in Turkey</h2>

<p>Turkey's pharmaceutical sector includes 300+ local manufacturers and 50+ multinational subsidiaries. Leading companies include:</p>
<ul>
<li><strong>Abdi İbrahim</strong> — one of Turkey's largest local manufacturers, operating AbdiBio, described as one of the country's largest biotech manufacturing investments, targeting monoclonal antibody production</li>
<li><strong>Eczacıbaşı</strong> — major local pharmaceutical and healthcare group</li>
<li><strong>Bilim İlaç</strong> — leading local generics and branded pharmaceutical manufacturer</li>
<li><strong>Sanovel</strong> — major local pharmaceutical manufacturer</li>
<li><strong>Deva Holding</strong> — local pharmaceutical manufacturer with API and finished-dose production</li>
<li><strong>Novartis Türkiye</strong> — multinational subsidiary</li>
<li><strong>Sanofi Türkiye</strong> — multinational subsidiary</li>
<li><strong>Pfizer Türkiye</strong> — multinational subsidiary</li>
<li><strong>Bayer Türkiye</strong> — multinational subsidiary</li>
<li><strong>Roche Group</strong> — multinational subsidiary</li>
</ul>
<p>This reflects the leading companies active in the Turkish pharmaceutical market rather than a single definitive ranked top-N — no one authoritative ranking source covers the full market, so treat this as a directory of major players rather than a scored ranking.</p>

<h2 id="market-entry">What this means for market entry</h2>

<p>Turkey's General Health Insurance system (SGK) covers approximately 98% of the population, making SGK reimbursement strategy central to any Turkey pharmaceutical launch. Combined with TITCK's five-country reference-pricing basket (Portugal, Spain, France, Italy, Greece), companies planning a Turkey launch need to sequence pricing decisions against those EU5-adjacent markets from the outset rather than treating Turkey pricing as an isolated decision. BioNixus positions Turkey research alongside its wider <a href="/gcc-pharma-market-report-2026">GCC pharmaceutical market</a> coverage, treating Turkey as a bridge market between Gulf launch sequencing and EU5 reference-pricing dynamics.</p>

<p>For BioNixus's Turkey-specific healthcare and devices intelligence, see the <a href="/healthcare-market-research/turkey">Turkey healthcare market research hub</a>, the <a href="/turkey-healthcare-market-report">Turkey Healthcare Market Report</a>, and the <a href="/turkey-medical-devices-market-report">Turkey Medical Devices Market Report</a>. To scope a Turkey market-entry or SGK access strategy programme, <a href="/contact">request a proposal</a>.</p>`;

export const TURKEY_PHARMA_2026_HARDCODED_POST: BlogPost = {
  id: 'hardcoded-turkey-pharma-2026',
  slug: TURKEY_PHARMA_2026_SLUG,
  title: TURKEY_PHARMA_2026_DISPLAY_TITLE,
  excerpt:
    "Turkey's pharmaceutical market in 2026: size and growth (IMARC: USD 10.5B in 2025 to USD 15.6B by 2035), TITCK's CTD/OAS registration process, five-country reference pricing, and the leading local and multinational companies.",
  date: '22 Jul 2026',
  category: 'Market Intelligence',
  country: 'Turkey',
  language: 'en',
  readingTime: 9,
  tags: [...TURKEY_PHARMA_2026_TAGS],
  coverImage: TURKEY_PHARMA_2026_COVER_IMAGE,
  ogImage: TURKEY_PHARMA_2026_COVER_IMAGE,
  ogTitle: TURKEY_PHARMA_2026_META_TITLE,
  ogDescription: TURKEY_PHARMA_2026_META_DESCRIPTION,
  seoMetaTitle: TURKEY_PHARMA_2026_META_TITLE,
  seoMetaDescription: TURKEY_PHARMA_2026_META_DESCRIPTION,
  seoCanonicalUrl: `https://www.bionixus.com/blog/${TURKEY_PHARMA_2026_SLUG}`,
  authorName: 'Laura Williams',
  authorTitle: 'Research Director, BioNixus Healthcare Market Research',
  publishedAtIso: TURKEY_PHARMA_2026_PUBLISHED_ISO,
  updatedAtIso: TURKEY_PHARMA_2026_UPDATED_ISO,
  tableOfContents: TURKEY_PHARMA_2026_TABLE_OF_CONTENTS,
  executiveSummary: TURKEY_PHARMA_2026_EXECUTIVE_SUMMARY_HTML,
  faq: [...TURKEY_PHARMA_2026_SCHEMA_FAQ],
  ctaSection: {
    title: 'Planning a Turkey pharmaceutical launch?',
    description:
      'BioNixus runs SGK-aligned market access research and positions Turkey launch strategy against GCC and EU5 reference-pricing dynamics.',
    buttonText: 'Talk to BioNixus',
    buttonUrl: 'https://www.bionixus.com/contact',
  },
  body: TURKEY_PHARMA_2026_BODY_HTML,
};
